AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.

AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer

Merck

In what could be the final approval for the year, the FDA OK'ed a label expansion Monday for Lynparza, which is being co-developed by Merck & Co.

Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer

AstraZeneca PLC (NYSE: AZN) has announced that the U.S. Food and Drug Administration (FDA) has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.

AstraZeneca’s FDA Nod Could Be Big

AstraZeneca (AZN) gets approval in China for PT010, its triple-combo inhaler, a fixed-dose ICS/LABA/LAMA inhaler, to treat COPD.

AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod

BeiGene

Seagen

The FDA was in a big hurry to make these new therapies available for patients who need them.

3 Blockbuster Cancer Drug Launches to Watch in 2020

AstraZeneca's (AZN) antibody drug conjugate candidate, Enhertu gets FDA approval for treating HER2-positive breast cancer in third or later-line setting.

AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu

AstraZeneca's (AZN) Imfinzi becomes the first immunotherapy to receive approval in China for treating unresectable, stage III NSCLC, which has not progressed following chemotherapy and radiation therapy.

AstraZeneca's Imfinzi Gets China Nod for Stage III NSCLC

There's a new treatment option on the way for breast cancer patients who have exhausted all their other options.

AstraZeneca May Have Knocked One Out of the Park

PayPal

Mondelez

Penumbra

World Wrestling Entertainment

Canaccord called Penumbra a "top, long-term" pick and said the stock has everything an investor should want.

Here are some of the best analyst calls of the week on Wall Street including PayPal, WWE

AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.

AstraZeneca's Lynparza Gets China Nod in First-Line Setting

AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.

AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC

Johnson & Johnson

These big drugmakers' CEOs have delivered strong total returns and enjoy widespread employee approval.

Like to Bet On the Jockey? Consider These 2 Big Pharma Stocks

Biotech is making great strides in oncology. “I think we are within striking distance of curing some cancers or actually improving survival rates to 90% or above,” AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot told CNBC of the field.

AstraZeneca CEO: Closing In On A Cancer Cure

AstraZeneca  shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie.

AstraZeneca shares rise on early U.S. approval for leukemia drug

The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.

AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

Global Payments

Lululemon Athletica

Motorola Solutions

Ping An Insurance Group Co of China Ltd

Roku

AT&T

These stocks are expected to new release products or services in the next year with massive sales potential, per analysis by Bloomberg Intelligence.

10 Stocks Poised for 'Blockbuster' Growth on Surging Sales

Novartis

Portola Pharmaceuticals

These three healthcare companies have a lot of good signs going for them.

3 'Top Healthcare' Stocks to Buy Now

Biopharmaceutical companies invest millions of dollars in their clinical pipeline, chasing that one elusive cure that can fetch them manifold returns when the program comes to fruition.

AstraZeneca Named The Most Innovative Global Pharma Company

AstraZeneca's stock has crushed its closest peers over the past three years. Can it keep heading higher?

AstraZeneca's Stock Is on a Roll. Time to Buy?

AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company.

AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial

AstraZeneca PLC (AZN) CEO Pascal Soriot on Q3 2019 Results - Earnings Call Transcript

AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.

News for AstraZeneca Stock (AZN)